BRIEF published on 07/16/2026 at 09:12, 1 month 6 days ago Valerio Therapeutics and Abivax join forces for innovative therapies Abivax Collaboration Inflammatory Diseases Valerio Therapeutics RNA Therapies
BRIEF published on 07/16/2026 at 09:12, 1 month 6 days ago Valerio Therapeutics et Abivax s'allient pour des thérapies innovantes Abivax Collaboration Maladies Inflammatoires Valerio Therapeutics Thérapies ARN
BRIEF published on 07/16/2026 at 09:12, 1 month 6 days ago Valerio Therapeutics s'associe à Abivax pour le développement de thérapies à base d'ARN Biotechnologie Valerio Thérapeutique Pipelines Thérapies À Base D'ARN Collaboration Abivax
BRIEF published on 07/16/2026 at 09:12, 1 month 6 days ago Valerio Therapeutics Partners with Abivax for RNA Therapeutics Development Biotechnology Valerio Therapeutics Pipelines RNA Therapeutics Abivax Collaboration
PRESS RELEASE published on 07/16/2026 at 09:07, 1 month 6 days ago Informations privilégiées / Autres communiqués Valerio Therapeutics annonce une collaboration de développement avec Abivax, met à jour son pipeline de thérapies de précision ARN Développement Abivax Collaboration Pipeline Valerio Therapeutics
PRESS RELEASE published on 07/16/2026 at 09:07, 1 month 6 days ago Inside Information / Other news releases Valerio Therapeutics partners with Abivax for global collaboration, providing pipeline update on RNA therapeutics. Initial payment up to €2.4 million Abivax Collaboration Valerio Therapeutics Pipeline Update RNA Therapeutics
BRIEF published on 07/01/2026 at 09:27, 1 month 21 days ago Valerio Therapeutics prépare l'acquisition d'Etherna Immunotherapies Valerio Therapeutics Investissement Biotechnologie Acquisition Etherna Médicaments ARN Fusion Entreprises
BRIEF published on 07/01/2026 at 09:27, 1 month 21 days ago Valerio Therapeutics Proposes to Acquire Etherna Immunotherapies Biotechnology Valerio Therapeutics Acquisition Deal RNA Medicines Etherna Immunotherapies
BRIEF published on 07/01/2026 at 09:27, 1 month 21 days ago Valerio Therapeutics propose d'acquérir Etherna Immunotherapies Biotechnologie Accord D'acquisition Valerio Thérapeutique Médicaments À Base D'ARN Immunothérapies Etherna
BRIEF published on 07/01/2026 at 09:27, 1 month 21 days ago Valerio Therapeutics is preparing to acquire Etherna Immunotherapies Valerio Therapeutics Biotechnology Investment Etherna Acquisition RNA Drugs Mergers Of Companies
Published on 08/22/2026 at 05:50, 5 hours 29 minutes ago Battery X Metals Provides Board of Directors Update
Published on 08/22/2026 at 04:55, 6 hours 24 minutes ago Vanta Announces Closing of First Tranche of Private Placement and Board of Directors Update
Published on 08/22/2026 at 00:30, 10 hours 49 minutes ago BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Published on 08/21/2026 at 23:00, 12 hours 19 minutes ago Tintina Mines Announces Voting Results from its Annual General and Special Meeting of Shareholders
Published on 08/21/2026 at 23:00, 12 hours 19 minutes ago Silver Storm Announces $7.5 Million Non-Brokered Private Placement with Eric Sprott
Published on 08/21/2026 at 19:36, 15 hours 43 minutes ago EQS-Adhoc: KAP AG ANNOUNCES CHANGE IN SHAREHOLDER STRUCTURE
Published on 08/21/2026 at 19:11, 16 hours 7 minutes ago EQS-Adhoc: Marley Spoon Group SE: Discussions with Misfits Market as permanent US fulfillment agent
Published on 08/21/2026 at 18:14, 17 hours 4 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/21/2026 at 17:27, 17 hours 52 minutes ago EQS-Adhoc: PSI Adjusts Its Forecast for Fiscal Year 2026 in Light of Economic Uncertainties in Europe
Published on 08/21/2026 at 16:30, 18 hours 48 minutes ago BL Networks (BLNWX) Details Major Global Infrastructure Expansion and Upgrades
Published on 08/21/2026 at 18:33, 16 hours 46 minutes ago 260821 BENETEAU Transaction sur actions propres
Published on 08/18/2026 at 18:00, 3 days 17 hours ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 3 days 17 hours ago Mise à disposition du rapport financier annuel 2025-26
